Revenue
$721.39K
Fiscal year ended 2026-06-30Operating income
-$48.96M
Fiscal year ended 2026-06-30Free cash flow
-$27.47M
Fiscal year ended 2026-06-30Co-Diagnostics, Inc. (CODX) reported revenue of $721.39K and net income of -$47.06M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Co-Diagnostics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.
Income
| Metric | 2026-06-30 |
|---|---|
| Revenue | $721.39K |
| Cost of revenue | $407.75K |
| Gross profit | $313.64K |
| Operating income | -$48.96M |
| Net income | -$47.06M |
| Research & development | $19.67M |
| Weighted-average diluted shares | Unavailable |
| Pretax income | -$48.68M |
| Income tax expense | -$1.62M |
| Diluted EPS | Unavailable |
| Selling, general & administrative | $9.74M |
| General & administrative | $7.69M |
| Selling & marketing | $2.05M |
Balance
| Metric | 2026-06-30 |
|---|---|
| Cash & equivalents | $3.65M |
| Total assets | $16.59M |
| Current assets | $5.19M |
| Total liabilities | $3.88M |
| Current liabilities | $2.86M |
| Total equity incl. NCI | $12.71M |
| Temporary (mezzanine) equity | Unavailable |
| Inventory | $841.67K |
| Accounts receivable | $52.06K |
| Goodwill | Unavailable |
| Long-term debt | Unavailable |
| Accounts payable | $1.08M |
Cash flow
| Metric | 2026-06-30 |
|---|---|
| Operating cash flow | -$27.10M |
| Capital expenditures | $367.37K |
| Investing cash flow | $1.54M |
| Financing cash flow | $18.10M |
| Net change in cash | -$7.47M |
| Stock-based compensation | $1.23M |
| Common dividends paid | Unavailable |
| Common share repurchases | Unavailable |
| Depreciation & amortization | $992.23K |
Derived
| Metric | 2026-06-30 |
|---|---|
| Free cash flow | -$27.47M |
| Gross margin | 43.5% |
| Operating margin | -6787.6% |
| FCF margin | -3808.0% |
| SBC / revenue | 169.9% |
| Current ratio | 1.81x |
| Revenue YoY growth | -28.1% |
| Net margin | -6523.0% |
| R&D / revenue | 2726.2% |
| CapEx / revenue | 50.9% |
| Long-term debt / equity | Unavailable |
| Effective tax rate | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CODX in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-08View SEC filing
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.